Lexicon Announces FDA Approval of INPEFA (Sotagliflozin) for Treatment of Heart Failure

INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF study 

Related Keywords

United States ,Americans ,America ,American ,Craig Granowitz ,Lexicon Pharmaceuticals Inc ,Heart Failure Society Of America ,Drug Administration ,American College Of Cardiology ,American Heart Association ,Lexicon Pharmaceuticals ,Lonnel Coats ,Worsening Heart Failure ,American College ,Heart Failure Society ,Guideline Directed Medical Therapy ,